Overview
Tmunity Therapeutics developed experimental T-cell therapies for cancer. The Philadelphia company drew on research at the University of Pennsylvania and raised substantial venture funding. Kite, a Gilead Sciences company, acquired Tmunity in February 2023 for its programs, technology, and research relationship with Penn. [1]
Its history includes a serious clinical setback: development of a prostate-cancer candidate stopped after two trial participants died from neurotoxicity. The later acquisition and eventual closure of Philadelphia operations are separate events. [2][3]
Founding Story
Tmunity was founded in 2015 around engineered T-cell research at Penn. Carl June and Bruce Levine were among its founders; Penn researchers James Riley and Anne Chew also held founding interests. Usman “Oz” Azam, formerly head of Novartis's cell and gene therapies unit, joined as CEO. Tmunity licensed Penn technologies and worked with the university as a discovery and early research partner. [1][4][5]
June and Levine had worked in the field as CAR T-cell therapies reached patients with certain blood cancers. Tmunity aimed to develop further engineered therapies, including approaches to solid tumors, where delivery and the tumor environment pose additional challenges. Those aims were research goals, not established clinical benefits. [4][6]
Timeline
- 2015: Tmunity was founded. [3]
- 2018: The company announced a $100 million Series A; Gilead and Penn were among participants. [5]
- 2019: Andreessen Horowitz led a $75 million Series B. [7]
- 2021: Tmunity stopped its lead prostate-cancer program after two deaths in a trial. [2]
- February 22, 2023: Kite completed its acquisition. [1]
- 2024–2025: Kite consolidated research into California and closed the remaining Philadelphia operation in June 2025. [3]
What They Built
CAR T-cell therapy typically involves collecting a patient's immune cells, engineering them to recognize a target, and returning them to the patient. Tmunity worked on next-generation engineered cells and manufacturing approaches. Kite said its acquisition included an “armored” CAR T platform, designed to add functions that might improve activity against tumors, and rapid manufacturing processes. These were experimental capabilities, not proof that a particular product would succeed. [1]
The company's lead prostate-cancer program targeted prostate-specific membrane antigen, or PSMA. A 2022 clinical review reported that two deaths from neurotoxicity occurred in a trial of PSMA-targeted CAR T cells equipped with a modified TGF-beta receptor. Tmunity stopped development of the candidate. The deaths concern that particular investigational program and should not be generalized to every CAR T treatment. [2][8]
Market Position
Target Customers
Tmunity developed potential therapies for patients with cancer. Physicians, regulators, treatment centers, and payers would all shape any eventual access, but the sources reviewed do not establish an approved Tmunity product. [1]
Market Size
The company pursued multiple cancer applications. A broad potential population did not establish a market for its investigational programs, which required clinical evidence and regulatory review. [4]
Competition
Kite and other companies already developed CAR T therapies, particularly for blood cancers. Tmunity's ambitions included solid tumors, where translating the approach had proved more difficult. Its Penn relationship and engineering platform were assets; the clinical setback showed the limits of assuming those assets would translate into a safe treatment. [1][6]
Business Model
Tmunity financed research and clinical development with private investment and held licensed university technology. Penn also held equity and received sponsored research funding. Kite disclosed that the university and several Penn scientists could receive future financial benefits under the license. The public sources do not establish Tmunity product revenue. [1]
Traction
Tmunity raised $100 million in its 2018 Series A and $75 million in its 2019 Series B. Those rounds funded an ambitious research program; they did not remove the safety and development risk that became visible in the prostate-cancer trial. [5][7]
Outcome and evolution
Clinical setback
In 2021, Tmunity halted the prostate program after two participants died from neurotoxicity. The trial's outcome is a concrete limitation on that candidate; it does not establish the reasons for every subsequent corporate decision. [2]
Acquisition and later closure
Kite completed the acquisition on February 22, 2023, adding Tmunity's platform, programs, and Penn research and licensing agreement. Gilead's 2023 resource book described the deal at approximately $300 million; its later annual report identified $269 million of acquired in-process research and development expense and $47 million of milestones met in 2024. These are different financial measures, not interchangeable deal prices. [1][9][10]
Kite later consolidated research in California. WHYY reported that the remaining 14 Philadelphia positions were eliminated and the site shut on June 30, 2025. The same report described continued Penn research supported by Kite. Closing a local operation did not prove that every acquired research relationship or program stopped. [3]
Key Lessons
- Treat trial safety as program-specific evidence. Tmunity stopped its prostate candidate after two deaths, despite substantial funding and experienced founders. [2]
- Follow the assets after a deal. Kite acquired both technology and a Penn research relationship, then later closed the Philadelphia site while supporting Penn research. [1][3]
Sources
- Kite confirms acquisition completion
- Fierce Biotech on halted prostate-cancer program
- WHYY on Philadelphia closure
- Andreessen Horowitz investment announcement
- BioCentury on Series A
- STAT on acquisition and solid-tumor challenges
- Fierce Biotech on Series B
- Clinical review of neurotoxicity
- Gilead 2023 resource book
- Gilead 2024 annual filing